TLOG
TetraLogic Pharmaceuticals CorporationNASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Tue, Nov. 22, 10:21 AM
    • In a regulatory filing, TetraLogic Pharmaceuticals (TLOG) discloses that on November 21 it issued 12,222,220 shares of its Series A convertible preferred stock to the holders of its 8% Convertible Senior Notes in exchange for the cancellation of $2.2M of the debt. The Series A stock is convertible at $0.18.
    | Tue, Nov. 22, 10:21 AM | 1 Comment
  • Wed, Nov. 2, 7:05 PM
    • Stockholm-based Medivir AB (OTC:MVRBF)(OTC:MVRBY) inks an agreement with TetraLogic Pharmaceuticals (NASDAQ:TLOG) to acquire two clinical-stage oncology programs.
    • The first, remetinostat, is an inhibitor of enzymes called histone deacetylases (HDACs) designed to be rapidly broken down in the bloodstream thereby avoiding the unwanted side effects associated with systemically administered HDAC inhibitors (e.g., nausea, vomiting, anemia, thrombocytopenia, neutropenia). It is currently in Phase 2 development for the treatment of early-stage cutaneous T-cell lymphoma. A Phase 3 study should commence in H2 2017.
    • The second, birinapant, is a bivalent second mitochondrial activator of caspases (SMAC) mimetic that binds a group of proteins called cellular inhibitor of apoptosis proteins (cIAPs), thereby promoting apoptosis (programmed cell death). Medivir intends to initiate two studies: a Phase 1 assessing birinapant in combination with Merck's Keytruda (pembrolizumab) in patients with solid tumors and a Phase 2 study assessing birinapant in combination with platinum-based chemo in high-grade serous carcinomas, including ovarian cancer.
    • Under the terms of the agreement, Tetralogic will receive an upfront payment of $12M, up to $96M in milestones for remetinostat, up to $130M in milestones for birinapant and sales-based tiered royalties of 13% for remetinostat and 10% for birinapant. The transaction should close by year end. Merck needs to sign off on an agreement transfer for birinapant considering its April 2015 license agreement with TetraLogic.
    • Previously: Merck and TetraLogic Pharma establish clinical study collaboration (April 20, 2015)
    | Wed, Nov. 2, 7:05 PM | 8 Comments
  • Fri, Jan. 29, 6:49 AM
    | Fri, Jan. 29, 6:49 AM | 5 Comments
  • Fri, Jan. 22, 9:27 AM
    • In a regulatory filing, TetraLogic Pharmaceuticals (NASDAQ:TLOG) discloses that it will cut 19 employees out of its 29-person workforce by next month. It will book a restructuring charge of $2.2M this quarter which may increase later in the year depending on facility-related charges and other write-downs that have yet to be finalized.
    • In connection with the job cuts, Chief Scientific Officer Dr. G. Glenn Begley and Chief Operating Officer Dr. Lesley Russell will be terminated effective April 19.
    • Earlier this month, shares plummeted after birinapant failed to beat placebo in a mid-stage study in myelodysplastic syndromes.
    • Previously: TetraLogic Pharma -69% after birinapant study shows no clinical benefit (Jan. 6)
    | Fri, Jan. 22, 9:27 AM | 1 Comment
  • Fri, Jan. 8, 5:50 PM
    • Illumina (NASDAQ:ILMN) saw a lot of action from analysts this week. Deutsche Bank initiated coverage with a Hold rating and $192 (16% upside) price target. Avondale Partners initiated with a Market Perform rating and $175 (6% upside) price target. Wells Fargo downgraded it to Market Perform from Outperform with a $170 - 180 price target. Cowen and Company reiterated its Outperform rating and raised its price target to $215 (30% upside). Barclays maintained its Equal Weight rating and raised its price target to $170 - 175.
    • TetraLogic Pharmaceuticals (NASDAQ:TLOG) initiated with Buy rating and $5 (1,463% upside) price target by Roth Capital.
    | Fri, Jan. 8, 5:50 PM | 2 Comments
  • Thu, Jan. 7, 12:41 PM
    | Thu, Jan. 7, 12:41 PM | 1 Comment
  • Thu, Jan. 7, 9:15 AM
    | Thu, Jan. 7, 9:15 AM | 20 Comments
  • Wed, Jan. 6, 6:38 PM
    • TetraLogic Pharmaceuticals (NASDAQ:TLOG) -68.8% AH after announcing that its Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes failed to demonstrate any clinical benefit over a placebo.
    • In a separate study, an interim analysis of a randomized Phase 2 clinical study of SHAPE, TLOG's proprietary topical HDAC inhibitor, eight of 34 patients showed a clinical benefit to treatment as assessed by CAILS, the primary endpoint.
    | Wed, Jan. 6, 6:38 PM | 16 Comments
  • Dec. 31, 2015, 12:40 PM
    | Dec. 31, 2015, 12:40 PM | 4 Comments
  • Dec. 31, 2015, 12:06 PM
    • TetraLogic Pharmaceuticals (TLOG +34.5%) initiated with Buy rating and $5 (170% upside) price target by Roth Capital.
    • Prima BioMed (PBMD +8.1%) initiated with Buy rating and $6 (400% upside) price target by Roth Capital.
    • Chimerix (CMRX +6.2%) downgraded to Neutral from Overweight JP Morgan. Price target lowered to $15 (69% upside) from $51. Barclays maintains Overweight rating but lowers price target to $12 from $64. Piper Jaffray maintains Overweight rating but lowers price target to $10 from $63. FBR downgrades to Market Perform and reduces price target to $14 from $73.
    | Dec. 31, 2015, 12:06 PM
  • Nov. 4, 2015, 6:19 PM
    • TetraLogic (NASDAQ:TLOG): Q3 EPS of -$0.39 beats by $0.03.
    | Nov. 4, 2015, 6:19 PM
  • Jul. 1, 2015, 9:10 AM
    • Thinly traded nano cap TetraLogic Pharmaceuticals (NASDAQ:TLOG) is up 30% premarket on light volume in response to its announcement of preliminary positive results in a small Phase 2a study of birinapant in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndromes (MDS).
    • Of the nine patients in the trial. three experienced a complete response, one a bone marrow complete response, one a partial response who then underwent a stem cell transplant and one had stable disease. The overall response rate was, therefore, 67% (n=6/9). Three patients discontinued the regimen prior to receiving four cycles of treatment.
    • A more complete interim analysis will be done later this year.
    • Birinapant is an SMAC-mimetic (Second Mitochondria-Derived Activator of Caspases) that binds to proteins called Inhibitor of Apoptosis proteins, or IAPs, that suppress apoptosis (cell death). 
    | Jul. 1, 2015, 9:10 AM | 3 Comments
  • Jun. 30, 2015, 5:36 PM
    | Jun. 30, 2015, 5:36 PM | 14 Comments
  • May 6, 2015, 12:45 PM
    | May 6, 2015, 12:45 PM
  • May 6, 2015, 10:48 AM
    • TetraLogic Pharmaceuticals (TLOG -59%) halts patient enrollment in a Phase 1 ascending dose trial of its lead product candidate, birinapant, in patients with chronic hepatitis B infection due to cranial nerve palsies observed in the first cohort. No additional details are provided.
    • Birinapant is also being investigated for the potential treatment of multiple cancers. It is an SMAC-mimetic that binds to proteins called Inhibitor of Apoptosis proteins, or IAPs, that suppress apoptosis (cell death). SMAC, Second Mitochondrial Activator of Caspases, is a naturally occurring IAP inhibitor. Cancer cells and cells infected with certain viruses (hep B) have apoptosis-escaping characteristics. Inhibiting the mechanisms that enable rogue cells to avoid cell death increases apoptosis and potentially delivers a therapeutic benefit.
    | May 6, 2015, 10:48 AM | 6 Comments
  • May 1, 2015, 12:45 PM
    | May 1, 2015, 12:45 PM